SG Americas Securities’s MoonLake Immunotherapeutics MLTX Stock Holding History

SG Americas Securities’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$180K	Sell	9,254 -96	-1%	-$1.74K	﹤0.01%	2848
2026 Q1	$174K	Sell	9,350 -12,538	-57%	-$208K	﹤0.01%	2705
2025 Q4	$288K	Buy	21,888 +4,362	+25%	+$51.5K	﹤0.01%	2770
2025 Q3	$126K	Buy	+17,526	New	+$913K	﹤0.01%	2984
2024 Q2	–	Sell	-14,458	Closed	-$726K	–	3129
2024 Q1	$726K	Buy	+14,458	New	+$784K	﹤0.01%	1274

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SG Americas Securities's MLTX Position: Q2 2026 in Review

SG Americas Securities reduced its MoonLake Immunotherapeutics (MLTX) stake by 1% in Q2 2026, selling an estimated $1.74K and leaving 9,254 shares worth $180K. The position accounts for ﹤0.01% of the portfolio, ranked #2848.

SG Americas Securities first reported a position in MLTX in Q1 2024 and has held it in 5 quarters since. The position peaked at $726K in Q1 2024. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

SG Americas Securities held 9,254 shares of MoonLake Immunotherapeutics worth $180K as of Q2 2026.
SG Americas Securities sold 96 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $1.74K.
MoonLake Immunotherapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #2848 holding.
SG Americas Securities first reported a position in MoonLake Immunotherapeutics in Q1 2024 and has held it in 5 quarters since.
SG Americas Securities's MoonLake Immunotherapeutics position peaked at $726K in Q1 2024.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.